Fluticasone propionate - Ellodi Pharmaceuticals
Alternative Names: APT 1011; EUR 1100Latest Information Update: 08 Oct 2024
At a glance
- Originator Aptalis
- Developer Adare Pharmaceuticals; Ellodi Pharmaceuticals
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Eosinophilic oesophagitis
Most Recent Events
- 12 Aug 2024 Ellodi Pharmaceuticals completes a phase III FLUTE-3 trial for Eosinophilic oesophagitis in USA and Canada (PO) (NCT05634746)
- 21 May 2024 Efficacy and adverse event data from the phase III FLUTE-2 trial in in Eosinophilic oesophagitis released by Ellodi Pharmaceuticals
- 29 Dec 2022 Ellodi Pharmaceuticals initiates a phase III FLUTE-3 trial for Eosinophilic oesophagitis (In adults, In the elderly) in USA (PO) (NCT05634746)